

Prematurely ended-statement

EudraCT Number: 2007-002023-32

Full title of trial: Niaspan for the treatment of endothelial dysfunction in patients without Hyperlipoproteinemia. (ENDOTHEN)

Protocol Code: NIASPAN

Sponsor: Charité – Universitätsmedizin Berlin

Sponsor Representative: Dr. med. Frank Spillmann
Medizinische Klinik m.S. Kardiologie
Campus Virchow-Klinikum
Medizinische Klinik m.S. Kardiologie
Augustenburger Platz 1, 13353 Berlin
frank.spillmann@charite.de

Product: Nicotinic acids (Niaspan/ Merck)

Date of the early Termination: 18.02.2013

Statement: On behalf of the Sponsor, it is hereby confirmed that the above study has been discontinued due to recruitment difficulties and the lack of marketing authorization of the preparation. No patient was included and treated.